(Q52975012)

10 May 2018

title

Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. (English)

1 reference

10 May 2018

1 reference

1 reference

1 reference

0 references

Tischer A

1

1 reference

10 May 2018

Gerike E

series ordinal

2

1 reference

10 May 2018

language of work or name

English

0 references

publication date

1 January 2000

1 reference

10 May 2018

published in

Vaccine

1 reference

10 May 2018

volume

18

1 reference

10 May 2018

page(s)

1382-1392

1 reference

10 May 2018

issue

14

1 reference

10 May 2018

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Mumps vaccines and meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Single point quantification of antibody by ELISA without need of a reference curve.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Virology of measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Comparative investigation of the long non-coding M-F genome region of wild-type and vaccine measles viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Measles antibody: reevaluation of protective titers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

The relationship between dose and response of standard measles vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Measles immunity and response to revaccination among secondary school children in Cumbria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Measles reimmunization in children seronegative after initial immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Mumps epidemic in Portugal despite high vaccine coverage - preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Comparison of the efficacy of various strains of mumps vaccine: a school survey

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Rubella immunity. Defining the level of protective antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Rubella reinfection; role of neutralising antibodies and cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900397-7

7 January 2021

10.1016/S0264-410X(99)00397-7

Identifiers

DOI

1 reference

10 May 2018

PubMed ID

10618536

1 reference

10 May 2018